News

PharmExec15h
Roche’s Next-Gen Bispecific Antibody Shows Early Promise in Hemophilia A
Early results from the Phase I/II NXTAGE trial show that NXT007 may achieve hemostatic normalization in patients with ...
The Pharma Letter22h
Roche’s Hemlibra successor moves to Phase III
Swiss pharma giant Roche has announced positive Phase I/II data on NXT007 in people with hemophilia A, supporting its ...